High flow nasal cannulae oxygen therapy in acute-moderate hypercapnic respiratory failure

Myoung Kyu Lee, Jaehwa Choi, Bonil Park, Bumjoon Kim, Seok Jeong Lee, Sangha Kim, Suk Joong Yong, Eun Hee Choi, Won Yeon Lee

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Introduction: Severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a significant event that results in substantial mortality. Objectives: We evaluated the effectiveness of the high flow nasal cannulae (HFNC) therapy in severe AECOPD with moderate hypercapnic acute respiratory failure (ARF) compared to non-invasive ventilation (NIV). Methods: The prospective observational trial was performed to compare the effectiveness between the HFNC and NIV in severe AECOPD with moderate hypercapnic ARF. The end point was the intubation rate and 30-day mortality. Results: Ninety-two AECOPD patients enrolled during study periods. The median age was 73 (66.5-79) years, and 57 patients (64.8%) were male. Forty-four patients were assigned to HFNC, and 44 patients were assigned to NIV. The intubation rate at day 30 was 25.0% in the HFNC group and 27.3% in the NIV group (P =.857), and the 30-day mortality was 15.9% in the HFNC group and 18.2% in the NIV group (P =.845). The pH (7.38 ± 0.59 vs 7.36 ± 0.10, P =.295), PaO2 (82.2 ± 24.9 vs 81.6 ± 21.7 mm Hg, P =.899) and PaCO2 (46.8 ± 15.2 vs 51.7 ± 17.2 mm Hg, P =.160) after 6 hours and the pH (7.39 ± 0.07 vs 7.39 ± 0.08, P =.743), PaO2 (84.3 ± 18.5 vs 84.7 ± 23.2 mm Hg, P =.934) and PaCO2 (47.0 ± 16.0 vs 49.6 ± 13.7 mm Hg, P =.422) after 24 hours were not significantly different. Conclusion: There was no difference of the 30-day mortality and intubation rate between HFNC and NIV groups.

Original languageEnglish
Pages (from-to)2046-2056
Number of pages11
JournalClinical Respiratory Journal
Volume12
Issue number6
DOIs
Publication statusPublished - 2018 Jun 1

Fingerprint

Noninvasive Ventilation
Respiratory Insufficiency
Oxygen
Chronic Obstructive Pulmonary Disease
Intubation
Mortality
Therapeutics
Cannula

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Genetics(clinical)

Cite this

Lee, Myoung Kyu ; Choi, Jaehwa ; Park, Bonil ; Kim, Bumjoon ; Lee, Seok Jeong ; Kim, Sangha ; Yong, Suk Joong ; Choi, Eun Hee ; Lee, Won Yeon. / High flow nasal cannulae oxygen therapy in acute-moderate hypercapnic respiratory failure. In: Clinical Respiratory Journal. 2018 ; Vol. 12, No. 6. pp. 2046-2056.
@article{e5bf3068c23b48c387812fb16ccdb971,
title = "High flow nasal cannulae oxygen therapy in acute-moderate hypercapnic respiratory failure",
abstract = "Introduction: Severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a significant event that results in substantial mortality. Objectives: We evaluated the effectiveness of the high flow nasal cannulae (HFNC) therapy in severe AECOPD with moderate hypercapnic acute respiratory failure (ARF) compared to non-invasive ventilation (NIV). Methods: The prospective observational trial was performed to compare the effectiveness between the HFNC and NIV in severe AECOPD with moderate hypercapnic ARF. The end point was the intubation rate and 30-day mortality. Results: Ninety-two AECOPD patients enrolled during study periods. The median age was 73 (66.5-79) years, and 57 patients (64.8{\%}) were male. Forty-four patients were assigned to HFNC, and 44 patients were assigned to NIV. The intubation rate at day 30 was 25.0{\%} in the HFNC group and 27.3{\%} in the NIV group (P =.857), and the 30-day mortality was 15.9{\%} in the HFNC group and 18.2{\%} in the NIV group (P =.845). The pH (7.38 ± 0.59 vs 7.36 ± 0.10, P =.295), PaO2 (82.2 ± 24.9 vs 81.6 ± 21.7 mm Hg, P =.899) and PaCO2 (46.8 ± 15.2 vs 51.7 ± 17.2 mm Hg, P =.160) after 6 hours and the pH (7.39 ± 0.07 vs 7.39 ± 0.08, P =.743), PaO2 (84.3 ± 18.5 vs 84.7 ± 23.2 mm Hg, P =.934) and PaCO2 (47.0 ± 16.0 vs 49.6 ± 13.7 mm Hg, P =.422) after 24 hours were not significantly different. Conclusion: There was no difference of the 30-day mortality and intubation rate between HFNC and NIV groups.",
author = "Lee, {Myoung Kyu} and Jaehwa Choi and Bonil Park and Bumjoon Kim and Lee, {Seok Jeong} and Sangha Kim and Yong, {Suk Joong} and Choi, {Eun Hee} and Lee, {Won Yeon}",
year = "2018",
month = "6",
day = "1",
doi = "10.1111/crj.12772",
language = "English",
volume = "12",
pages = "2046--2056",
journal = "Clinical Respiratory Journal",
issn = "1752-6981",
publisher = "Wiley-Blackwell",
number = "6",

}

Lee, MK, Choi, J, Park, B, Kim, B, Lee, SJ, Kim, S, Yong, SJ, Choi, EH & Lee, WY 2018, 'High flow nasal cannulae oxygen therapy in acute-moderate hypercapnic respiratory failure', Clinical Respiratory Journal, vol. 12, no. 6, pp. 2046-2056. https://doi.org/10.1111/crj.12772

High flow nasal cannulae oxygen therapy in acute-moderate hypercapnic respiratory failure. / Lee, Myoung Kyu; Choi, Jaehwa; Park, Bonil; Kim, Bumjoon; Lee, Seok Jeong; Kim, Sangha; Yong, Suk Joong; Choi, Eun Hee; Lee, Won Yeon.

In: Clinical Respiratory Journal, Vol. 12, No. 6, 01.06.2018, p. 2046-2056.

Research output: Contribution to journalArticle

TY - JOUR

T1 - High flow nasal cannulae oxygen therapy in acute-moderate hypercapnic respiratory failure

AU - Lee, Myoung Kyu

AU - Choi, Jaehwa

AU - Park, Bonil

AU - Kim, Bumjoon

AU - Lee, Seok Jeong

AU - Kim, Sangha

AU - Yong, Suk Joong

AU - Choi, Eun Hee

AU - Lee, Won Yeon

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Introduction: Severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a significant event that results in substantial mortality. Objectives: We evaluated the effectiveness of the high flow nasal cannulae (HFNC) therapy in severe AECOPD with moderate hypercapnic acute respiratory failure (ARF) compared to non-invasive ventilation (NIV). Methods: The prospective observational trial was performed to compare the effectiveness between the HFNC and NIV in severe AECOPD with moderate hypercapnic ARF. The end point was the intubation rate and 30-day mortality. Results: Ninety-two AECOPD patients enrolled during study periods. The median age was 73 (66.5-79) years, and 57 patients (64.8%) were male. Forty-four patients were assigned to HFNC, and 44 patients were assigned to NIV. The intubation rate at day 30 was 25.0% in the HFNC group and 27.3% in the NIV group (P =.857), and the 30-day mortality was 15.9% in the HFNC group and 18.2% in the NIV group (P =.845). The pH (7.38 ± 0.59 vs 7.36 ± 0.10, P =.295), PaO2 (82.2 ± 24.9 vs 81.6 ± 21.7 mm Hg, P =.899) and PaCO2 (46.8 ± 15.2 vs 51.7 ± 17.2 mm Hg, P =.160) after 6 hours and the pH (7.39 ± 0.07 vs 7.39 ± 0.08, P =.743), PaO2 (84.3 ± 18.5 vs 84.7 ± 23.2 mm Hg, P =.934) and PaCO2 (47.0 ± 16.0 vs 49.6 ± 13.7 mm Hg, P =.422) after 24 hours were not significantly different. Conclusion: There was no difference of the 30-day mortality and intubation rate between HFNC and NIV groups.

AB - Introduction: Severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a significant event that results in substantial mortality. Objectives: We evaluated the effectiveness of the high flow nasal cannulae (HFNC) therapy in severe AECOPD with moderate hypercapnic acute respiratory failure (ARF) compared to non-invasive ventilation (NIV). Methods: The prospective observational trial was performed to compare the effectiveness between the HFNC and NIV in severe AECOPD with moderate hypercapnic ARF. The end point was the intubation rate and 30-day mortality. Results: Ninety-two AECOPD patients enrolled during study periods. The median age was 73 (66.5-79) years, and 57 patients (64.8%) were male. Forty-four patients were assigned to HFNC, and 44 patients were assigned to NIV. The intubation rate at day 30 was 25.0% in the HFNC group and 27.3% in the NIV group (P =.857), and the 30-day mortality was 15.9% in the HFNC group and 18.2% in the NIV group (P =.845). The pH (7.38 ± 0.59 vs 7.36 ± 0.10, P =.295), PaO2 (82.2 ± 24.9 vs 81.6 ± 21.7 mm Hg, P =.899) and PaCO2 (46.8 ± 15.2 vs 51.7 ± 17.2 mm Hg, P =.160) after 6 hours and the pH (7.39 ± 0.07 vs 7.39 ± 0.08, P =.743), PaO2 (84.3 ± 18.5 vs 84.7 ± 23.2 mm Hg, P =.934) and PaCO2 (47.0 ± 16.0 vs 49.6 ± 13.7 mm Hg, P =.422) after 24 hours were not significantly different. Conclusion: There was no difference of the 30-day mortality and intubation rate between HFNC and NIV groups.

UR - http://www.scopus.com/inward/record.url?scp=85043227760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043227760&partnerID=8YFLogxK

U2 - 10.1111/crj.12772

DO - 10.1111/crj.12772

M3 - Article

C2 - 29392846

AN - SCOPUS:85043227760

VL - 12

SP - 2046

EP - 2056

JO - Clinical Respiratory Journal

JF - Clinical Respiratory Journal

SN - 1752-6981

IS - 6

ER -